Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,347 result(s) found. Displaying page 1,852 of 2,218.
    «« First « Previous 1848  1849  1850  1851  1852  1853  1854  1855  1856  Next» Last»»
    EudraCT Number: 2017-001123-53 Sponsor Protocol Number: MK-3475-667 Start Date*: 2019-06-14
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response...
    Medical condition: cHL in children and young adults
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10080208 Classical Hodgkin lymphoma LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA DE (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) IT (Trial now transitioned) SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000681-10 Sponsor Protocol Number: I1F-MC-RHCG Start Date*: Information not available in EudraCT
    Sponsor Name:Eli Lilly and Company
    Full Title: Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab with Adalimumab Reference Arm, in Children with Juvenile Idiopathic Arthritis Subtypes ...
    Medical condition: Juvenile Idiopathic Arthritis subtypes of enthesitis-related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) DK (Prematurely Ended) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000944-82 Sponsor Protocol Number: MK-3475-966 Start Date*: 2020-03-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectabl...
    Medical condition: Advanced and/or Unresectable Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, or Gallbladder)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10004655 Biliary carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000496-20 Sponsor Protocol Number: INCMGA0012-204 Start Date*: 2021-01-08
    Sponsor Name:Incyte Corporation
    Full Title: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemothe...
    Medical condition: Endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014734 Endometrial cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned) DE (Prematurely Ended) BE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003001-94 Sponsor Protocol Number: MSGLP Start Date*: 2019-11-06
    Sponsor Name:Lekárska fakulta UK Bratislava
    Full Title: Use of GLP-1 analogs in the treatment of multiple sclerosis
    Medical condition: Our hypothesis is that patients with MS have a disorder of energy metabolism in neurons and glial cells of the CNS, contributing to the development and progression of demyelinating foci and neurode...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002479-37 Sponsor Protocol Number: 1404-0036 Start Date*: 2021-03-15
    Sponsor Name:Boehringer Ingelheim AB
    Full Title: A Phase II, randomized, double blind, parallel group,46 weeks dose-finding study of BI 456906 administered once weekly subcutaneously compared with placebo in patients with obesity or overweight
    Medical condition: obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IE (Prematurely Ended) NL (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000506-37 Sponsor Protocol Number: GNT-012-CRIG Start Date*: 2018-04-05
    Sponsor Name:Genethon
    Full Title: CareCN: A phase I/II, open label, escalating dose study to evaluate safety and efficacy of an intravenous injection of GNT0003 (Adeno-associated Viral Vector expressing the UGT1A1 transgene) in pat...
    Medical condition: severe Crigler Najjar syndrome in patients requiring phototherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011386 Crigler-Najjar syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002667-34 Sponsor Protocol Number: WA39085 Start Date*: 2020-03-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL, PARALLEL-GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF OCRELIZUMAB IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTING MULTIPLE SCLE...
    Medical condition: Relapsing-remitting multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    20.1 10029205 - Nervous system disorders 10039720 Sclerosis multiple LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003956-35 Sponsor Protocol Number: MK-3475-02A Start Date*: 2020-03-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
    Full Title: A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02A
    Medical condition: Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Prematurely Ended) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004048-27 Sponsor Protocol Number: 849-010 Start Date*: 2022-02-09
    Sponsor Name:Mirati Therapeutics, Inc.
    Full Title: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Stan...
    Medical condition: Advanced Colorectal Cancer with KRAS G12C Mutation
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) PT (Trial now transitioned) FI (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003307-16 Sponsor Protocol Number: OMT28-C0203 Start Date*: 2023-04-18
    Sponsor Name:OMEICOS Therapeutics GmbH
    Full Title: A Phase 2a Safety, Tolerability, and Pharmacodynamic Study of OMT-28 in PMD patients with myopathy and/or cardiomyopathy and inflammation (PMD-OPTION)
    Medical condition: Primary Mitochondrial Disease (PMD)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10010331 - Congenital, familial and genetic disorders 10052641 Mitochondrial DNA mutation PT
    22.0 10010331 - Congenital, familial and genetic disorders 10052641 Mitochondrial DNA mutation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003417-35 Sponsor Protocol Number: PARPA-293-002 Start Date*: 2021-11-10
    Sponsor Name:Nerviano Medical Sciences S.r.l
    Full Title: A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients with Recurrent Glioblastoma
    Medical condition: Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002336-74 Sponsor Protocol Number: SGN35-032 Start Date*: 2020-12-08
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression
    Medical condition: Non-sALCL PTCL and CD30 expression <10%
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10034624 Peripheral T-cell lymphoma unspecified NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004285-35 Sponsor Protocol Number: CA224-123 Start Date*: 2022-07-12
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Open-label (Sponsor Blinded) Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines o...
    Medical condition: Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000875-37 Sponsor Protocol Number: VanC-IT Start Date*: 2022-11-03
    Sponsor Name:UNIVERSITÀ DEGLI STUDI MILANO BICOCCA
    Full Title: A Prospective, Randomized, Placebo-controlled Clinical Trial of oral vancomycin in adults and young adults (15-17 years old) affected by Primary Sclerosing Cholangitis with or without Inflammatory ...
    Medical condition: Primary Sclerosing Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004871 10036732 Primary sclerosing cholangitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000614-37 Sponsor Protocol Number: 21467 Start Date*: 2019-05-02
    Sponsor Name:Region Örebro Län
    Full Title: Kort-SGS: Does a series of intralesional steroid injections after endoscopic treatments for subglottic stenosis prolong interval between between surgical interbentions? A prospective single blinded...
    Medical condition: Subglottic stenosis: Idiopatic, autoimmune, traumatic.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000761-16 Sponsor Protocol Number: ALXN1210-TMA-314 Start Date*: Information not available in EudraCT
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age) with Thrombotic Microangiopathy...
    Medical condition: hematopoietic stem cell transplant-associated thrombotic microangiopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043645 Thrombotic microangiopathy PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006629-23 Sponsor Protocol Number: 61186372GIC2002 Start Date*: 2022-08-23
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer
    Medical condition: Advanced or Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-006274-29 Sponsor Protocol Number: ZEMPLAR Start Date*: 2009-11-18
    Sponsor Name:Karolinska Institutet at Danderyd University Hospital
    Full Title: Sympathetic activation, microcirculation, haemostasis and inflammation in diabetic and non-diabetic kidney disease: disease modification by vitamin D receptor activation
    Medical condition: Patients with mild to moderate chronic renal failure (CRF; GFR 15-60ml/min; n=26) Patients with mild to moderate CRF and coexisting Diabetes Mellitus (n=26)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064848 Chronic kidney disease LLT
    12.0 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000317-14 Sponsor Protocol Number: RAD-GRIN-101 Start Date*: 2022-11-28
    Sponsor Name:GRIN Therapeutics, Inc.
    Full Title: A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Multiple Individually Titrated Doses of Radiprodil in Children with GRIN-...
    Medical condition: gain of function (GoF) variants in the GRIN2B gene
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10064062 Neurodevelopmental disorder PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1848  1849  1850  1851  1852  1853  1854  1855  1856  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 06 13:41:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA